These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 32413077)

  • 1. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
    Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
    PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma.
    Zschaeck S; Wust P; Graf R; Misch M; Onken J; Ghadjar P; Badakhshi H; Florange J; Budach V; Kaul D
    Radiat Oncol; 2018 Dec; 13(1):251. PubMed ID: 30567592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
    Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
    J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
    Chen L; Guerrero-Cazares H; Ye X; Ford E; McNutt T; Kleinberg L; Lim M; Chaichana K; Quinones-Hinojosa A; Redmond K
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):616-22. PubMed ID: 23540348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of multiple glioblastomas: An analysis of prognostic factors and survival to distinguish from their single counterparts.
    Shieh LT; Guo HR; Chang YK; Lu NM; Ho SY
    J Formos Med Assoc; 2020 Mar; 119(3):728-734. PubMed ID: 31515159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis.
    Lee P; Eppinga W; Lagerwaard F; Cloughesy T; Slotman B; Nghiemphu PL; Wang PC; Kupelian P; Agazaryan N; Demarco J; Selch MT; Steinberg M; Kang JJ
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):609-15. PubMed ID: 23462418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
    Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
    Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
    Azoulay M; Santos F; Souhami L; Panet-Raymond V; Petrecca K; Owen S; Guiot MC; Patyka M; Sabri S; Shenouda G; Abdulkarim B
    Radiat Oncol; 2015 Apr; 10():106. PubMed ID: 25927334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of subventricular zone irradiation on outcome of patients with glioblastoma.
    Mathew BS; Kaliyath SB; Krishnan J; Bhasi S
    J Cancer Res Ther; 2018; 14(6):1202-1206. PubMed ID: 30488830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial.
    Ballo MT; Urman N; Lavy-Shahaf G; Grewal J; Bomzon Z; Toms S
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1106-1113. PubMed ID: 31026557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
    Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
    Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.